Sounds like Takeda is still hoping to not have to wait for the outcomes trial. If they do, then any possible approval is likely three or four years out.
Furiex has an interesting IB-d drug - not sure what else they have.
The FDA issued a CRL on these NDAs in Apr 2012, but stopped short of demanding a new trial (#msg-74854335). Alogliptin is a DPP-4 inhibitor, i.e. from the same class as MRK’s Januvia. Actos is a big-selling drug that Takeda has been marketing since the 1990s; it goes off-patent in the US in 2016.
News 
Market Data 
Discover 
AI
